Document is current

Article History

Received: 30 November 2024

Accepted: 31 March 2025

First Online: 16 April 2025

Declarations

:

: Information was individually provided to the patients and caregivers, and oral consent had to be obtained to participate, as required by the French committee for this type of study. The MEMORA cohort protocol (clinicaltrial.gov number NCT02302482) has been approved by the regional ethics committee (Comité de protection des personnes Sud Est III) on July 29, 2014, the Advisory Committee on Information Processing in Material Research in the Field of Health, and the National Commission for Data Protection and Liberties (CNIL). These approvals are in line with the principles of the Helsinki Declaration.

: Not applicable.

: The authors declare no competing interests.

: Independent of this work, A.G.C is an unpaid sub-investigator or local principal investigator in NCT04867616 (UCB Pharma), NCT04241068 (Biogen), NCT05310071 (Biogen), NCT03446001 (TauRx Therapeutics), NCT03444870 (Roche), NCT04374253 (Roche), NCT04777396 (Novo Nordisk), NCT04777409 (Novo Nordisk), NCT04770220 (Alzheon), NCT05423522 (Medesis Pharma), NCT06079190 (GlaxoSmithKline).M.N.T, C.Mt, C.Mc and VD declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. This manuscript has not been published or submitted elsewhere. All authors have contributed significantly, and all authors are in agreement with the content of the manuscript.

: During the preparation of this work the first author (M.N.T) used ChatGPT in order to correct English mistakes. After using this tool, the authors reviewed and edited the content as needed and takes full responsibility for the content of the published article.